Participant Protection in Phase 1 Pediatric Cancer Trials
This Viewpoint describes changes in the regulatory environment for phase 1 research involving children and discusses improvements to patient protection.
Related Articles
FDA Approves First Twice-Yearly PrEP for Long-Acting HIV Prevention
The US Food and Drug Administration (FDA) recently approved lenacapavir, marketed as Yeztugo, as the first twice-yearly preexposure prophylaxis (PrEP) that reduces HIV risk.
Endocrine Society (ENDO)
Explore special articles published online first to coincide with presentations at the Endocrine Society (ENDO).
Endocrine Society (ENDO)
Explore special articles published online first to coincide with presentations at the Endocrine Society (ENDO).
Education, Lifestyle, and Treatment Choices and Multiple Sclerosis Progression
This cohort study evaluates the association between educational level and disability progression in patients with multiple sclerosis.
Use of Tobacco and Cannabis Following State-Level Cannabis Legalization
This cohort study assesses whether there were changes in the use of cannabis, cigarettes, and electronic nicotine delivery systems among US adults during 5 years…
Endocrine Society (ENDO)
Explore special articles published online first to coincide with presentations at the Endocrine Society (ENDO).
Patient With Hemoptysis and a Laryngeal Mass
A 76-year-old man presented to the emergency department with a 6-week history of globus sensation and muffled voice and acute onset frank hemoptysis. Laryngoscopy revealed…
Biomarker Testing, Treatment Selection, and Cost of Care for Adults With Cancer
This cohort study of adults with advanced cancer compares the use of targeted therapy during first-line therapy for patients with no biomarker testing, comprehensive genomic…
Endocrine Society (ENDO)
Explore special articles published online first to coincide with presentations at the Endocrine Society (ENDO).
New GLP-1 Combos and Other Highlights From ADA 2025
This Medical News article is an interview with Raveendhara Bannuru, MD, PhD, vice president of medical affairs at the American Diabetes Association, about clinical highlights…